News &amp; Updates

Exposure to valproate during spermatogenesis does not appear to put infants at risk of congenital malformations or neurodevelopmental disorders, including autism spectrum disorder, according to a study.

Valproate exposure during spermatogenesis carries no harm in offspring

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ARASENS post hoc sensitivity analysis data presented at ASCO GU 2024 support primary OS analysis and demonstrate that darolutamide + ADT + docetaxel is an effective, well-tolerated SoC for mHSPC.

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

Blood-based CRC screening platform delivers promising performance

An investigational blood-based test performs satisfactorily for the early detection of colorectal cancer (CRC), having met all prespecified primary endpoints in the large PREEMPT CRC trial.

Blood-based CRC screening platform delivers promising performance

13 Jun 2024

Fatigue, pain weigh down people with fibromyalgia

Several symptoms of individuals with fibromyalgia (FM), including fatigue and sleep disturbance, have significant impacts on their daily life, and the prevalence of such symptoms may vary depending on demographic categories and disability status, according to a study.

Fatigue, pain weigh down people with fibromyalgia

13 Jun 2024

Intense exercise safe for men with metastatic prostate cancer

Patients with metastatic prostate cancer can safely engage in intense exercise training to improve survival outcomes, suggests a study presented at AACR 2024.

Intense exercise safe for men with metastatic prostate cancer

13 Jun 2024

Telemedicine works well in acute coronary syndrome

Remote assessment appears effective in reducing hospital readmission, emergency department (ED) visits, unplanned revascularization, and patient-reported symptoms following an acute coronary syndrome (ACS), reports a study.

Telemedicine works well in acute coronary syndrome

13 Jun 2024

Are fertility treatments safe in young breast cancer survivors who have high-risk genes?

In young breast cancer survivors harbouring BRCA1/2 pathogenic variants, using assisted reproductive techniques (ART) to conceive did not appear to negatively affect maternal or pregnancy outcomes, findings from an international retrospective cohort study suggest.

Are fertility treatments safe in young breast cancer survivors who have high-risk genes?

13 Jun 2024

Optimizing first-and subsequent-line therapy for advanced RCC

The treatment landscape of metastatic renal cell carcinoma (mRCC) has undergone a major transformation in the past two decades, with interleukin-2 and interferon-α being replaced with anti-angiogenic tyrosine kinase inhibitors (TKIs), inhibitors of mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors (ICIs). At an Eisai-sponsored symposium organized by the Hong Kong Society of Uro-Oncology during Uro-Oncology Asia 2024, Professor Sun-Young Rha of the Yonsei University College of Medicine in Seoul, South Korea, discussed the importance of optimizing first-line treatment and subsequent strategies for patients with advanced RCC. Rha also reviewed clinical evidence on regimens containing lenvatinib (Lenvima^®, Eisai), an oral TKI against VEGF receptor, which have been shown to improve outcomes in first and subsequent lines of therapy.

Optimizing first-and subsequent-line therapy for advanced RCC

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer held in San Diego, US, researchers presented updated results from the two-part, phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) associated with dostarlimab-based combinations in patients with primary advanced or recurrent endometrial cancer (EC).

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

Use of an anti-CD38 mAb in a transplant-ineligible patient with newly diagnosed multiple myeloma

A 66-year-old man with plasma cell myeloma and high-risk cytogenetic abnormality was referred to our centre in September 2022. He previously visited a private clinic in August 2022 for back and rib pain, where he received his earlier diagnosis. He was a smoker and chronic drinker with a history of hypertension. His Eastern Cooperative Oncology Group performance status (ECOG PS) was 0–1.

Use of an anti-CD38 mAb in a transplant-ineligible patient with newly diagnosed multiple myeloma